HDFC Pharma and Healthcare Fund Direct Growth
HDFC Pharma and Healthcare Fund Direct Growth: NAV ₹23.52, 3Y return 30.58%, AUM ₹2,940 Cr, expense ratio 1.08%, iNVESTT rating 5/5. Returns vs index, rolling returns, holdings, Direct vs Regular and peers, by a SEBI Registered Research Analyst.
Key facts
- NAV
- ₹23.5160 (19 Nov 2026)
- 1-year return
- 31.61%
- 3-year return (CAGR)
- 30.58%
- Fund size (AUM)
- ₹2,940 Cr
- Expense ratio
- 1.08%
- Exit load
- In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment.
- Minimum investment
- 100
- Category
- Sectoral Fund
- Benchmark
- BSE Healthcare Index (TRI)
- Riskometer
- Very High Risk
- Fund manager
- FM 1 - Mr. Nikhil Mathur, FM 2 - Mr. Gopal Agrawal, FM 3 - Mr. Bhagyesh Kagalkar
- Launch date
- 14 Sept 2023
- iNVESTT rating
- 5 out of 5
Frequently asked questions
What is the NAV of HDFC Pharma and Healthcare Fund Direct Growth today?
The NAV of HDFC Pharma and Healthcare Fund Direct Growth is ₹23.5160 as of 19 Nov 2026.
What are the returns of HDFC Pharma and Healthcare Fund Direct Growth?
31.61% over 1 year, 30.58% a year over 3 years. Past returns do not guarantee future returns; compare them with the benchmark and rolling returns on this page.
What is the expense ratio of HDFC Pharma and Healthcare Fund Direct Growth?
The expense ratio (TER) is 1.08% a year.
What is the AUM (fund size) of HDFC Pharma and Healthcare Fund Direct Growth?
HDFC Pharma and Healthcare Fund Direct Growth manages ₹2,940 Cr.
Is there an exit load on HDFC Pharma and Healthcare Fund Direct Growth?
Exit load: In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment..
How risky is HDFC Pharma and Healthcare Fund Direct Growth?
Its SEBI riskometer is "Very High Risk" and it is in the Sectoral Fund category.
What is the benchmark of HDFC Pharma and Healthcare Fund Direct Growth?
The benchmark is BSE Healthcare Index (TRI). This page compares the fund with its benchmark's total-return index (TRI).
What is the iNVESTT rating of HDFC Pharma and Healthcare Fund Direct Growth?
5 out of 5. iNVESTT rating: where the fund ranks in its category over 1, 3 and 5 years (3 and 5 years count most). Top fifth = 5 stars. A past-performance measure, not a recommendation.
Research by iNVESTT, a SEBI Registered Research Analyst (INH000010858). Data from AMFI. Mutual fund investments are subject to market risks; past performance does not guarantee future returns.